by Market Players Focus on Improving Existing Chronic Idiopathic Constipation Therapies
Chronic idiopathic constipation is a highly prevalent functional bowel disorder that affects millions of individuals worldwide. Some of the major factors that contribute to the burgeoning number of patients suffering from chronic idiopathic constipation include sedentary lifestyle, increasing usage of anti-inflammatory agents, and drastic decline in the intake of dietary fibers. Over the past few years, considerable efforts have been made to improve the management of chronic idiopathic constipation. In the current scenario, empiric therapy has garnered considerable attention from the stakeholders operating in the current chronic idiopathic constipation treatment market – a trend that is expected to continue during the forecast period.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111832
Researchers involved in the current chronic idiopathic constipation treatment market landscape are also increasingly focusing on the development of customized treatment plans that offer multi-symptom relief. Efforts are being made to improve the efficacy of the current therapeutic agents due to which, a steady growth of the global chronic idiopathic constipation treatment market is anticipated in the upcoming years. A number of players involved in the current market for chronic idiopathic constipation treatment are focusing on gaining approval from the FDA for the newly developed drugs and treatments.
At the back of these factors, along with the augmenting demand for chronic idiopathic constipation treatment, the global chronic idiopathic constipation treatment market is expected to surpass the US$ 15.9 Bn mark by the end of 2030.
Consistent Progress in Management of Chronic Idiopathic Constipation to Bolster Market Growth
In the initial stages, chronic idiopathic constipation treatment primarily included a blend of medication review, lifestyle modifications, and patient education. While prescription treatments are expected to witness considerable adoption worldwide, a number of non-prescription chronic idiopathic constipation treatments, including fiber supplementation, has garnered popularity. Moreover, research activities suggest that soluble fibers such as psyllium offer relief to patients suffering from chronic idiopathic constipation in comparison with insoluble fibers including bran. The increasing usage of soluble fibers has led to a noteworthy improvement in global symptoms and stool consistency due to which, the chronic idiopathic constipation treatment market is largely leaning toward the utilization of soluble fibers in the empiric fiber therapy. The rising usage of osmotic laxatives, stimulant laxative, and bulking laxatives is expected to contribute to the growth of the global chronic idiopathic constipation treatment market as the demand for non-prescription treatments continues to move in the upward trajectory.
While non-prescription treatments are gradually gaining worldwide adoption, the demand for prescription treatments is on the rise. However, players operating in the current chronic idiopathic constipation treatment market landscape are increasingly focusing on catering to the unmet needs with existing chronic idiopathic constipation treatment alternatives.
Unpredictability, poor symptom relief, bloating, and inability to enhance the quality of life of current treatments have compelled companies in the current market for chronic idiopathic constipation treatment to introduce better prescription agents and mechanisms. Some of the recently developed prescription agents that are gaining fast-paced adoption include prosecretory agents and a host of FDA approved products such as linaclotide.
FDA Approval of New Drugs to Aid Market Growth
In the current scenario, manufacturers operating in the chronic idiopathic constipation treatment market are increasingly seeking the approval of the FDA for their newly developed drugs. Gaining the approval of the FDA is expected to remain one of the core areas of focus for the chronic idiopathic constipation drug manufacturers over the course of the forecast period. A number of drugs has received the green signal from the FDA in recent years.
In February 2020, the U.S. FDA approved an osmotic laxative developed by the Braintree Laboratories to treat chronic idiopathic constipation among adults. While attaining the FDA approval is expected to remain a top priority, market players are likely to increase the R&D spending on the development of new therapeutics and products.
Moderate Impact of COVID-19 Pandemic on Global Market
The onset of the COVID-19 pandemic is expected to have a moderate impact on the global chronic idiopathic constipation treatment market in 2020. The first quarter of 2020 witnessed steady ascension in the demand for chronic idiopathic constipation treatment worldwide. However, outbreak of the COVID-19 pandemic toward the end of the first quarter and stringent lockdown measures implemented by governments in the second and the third quarter of 2020 are expected to negatively affect the adoption of chronic idiopathic constipation treatment. However, the demand is set to witness considerable growth toward the end of 2020, as governments around the world continue to lift the lockdown measures in a phased manner.
Stuck in a neck-to-neck competition with other brands? Request a custom report on Chronic Idiopathic Constipation Treatment Market
Analysts’ Viewpoint
The global chronic idiopathic constipation treatment market is expected to grow at a healthy CAGR of ~7% during the forecast period. The market growth can be primarily attributed to factors such as increasing prevalence of chronic idiopathic constipation among adults worldwide, high demand for improved chronic idiopathic constipation treatment and therapies to address unmet needs of existing treatments, and research and development activities. Market players should focus on the development of new prescription as well as non-prescription chronic idiopathic constipation treatments and continue to invest in R&D activities.
Chronic Idiopathic Constipation Treatment Market: Overview
The global chronic idiopathic constipation treatment market for the historical period 2018–2019 and forecast period 2020–20230, promising pipeline is anticipated to drive the global m chronic idiopathic constipation treatment market
Constipation is a highly common chronic gastrointestinal disorder. Chronic idiopathic constipation (CIC) is a health condition in which a patient experiences chronic symptoms of constipation. Changing dietary habits, i.e., reduction in fluid and fiber intake in diet, changes in water balance, and changes in contractility of the colon cause chronic idiopathic constipation.
Increase in Demand for CIC Treatment Products to Drive Chronic Idiopathic Constipation Treatment Market
Steady rise in prevalence of constipation across the global population is leading to high demand for newer therapeutics. This, in turn, is estimated to drive the market. Healthcare providers and patients both report unmet needs with current chronic idiopathic constipation treatment options.
Around 50% of patients with chronic idiopathic constipation report dissatisfaction with non-prescription laxatives due to unpredictability, bloating, poor symptom relief, or inability to improve quality of life. Alternative agents with novel mechanisms of action are being developed for the last 10 years in order to address these concerns.
Likewise, several of the available specialty drugs are intended for use in adolescents and adult patients. Surge in incidence of constipation among children is likely to present significant opportunities for key players and new entrants to develop and launch specialty constipation drugs for pediatric use.
Rise in Healthcare Spending and Improvements in Healthcare Infrastructure Propel Chronic Idiopathic Constipation Treatment Market
Increase in the number of patients with chronic idiopathic constipation boosts adoption of newer products. Patients are more aware and proactive about their health, and are willing to seek effective treatment. Hence, rise in healthcare spending on constipation is likely to boost the market.
An article published in the American Journal of Managed Care in 2007 stated that people in the U.S. spent more than US$ 800 million on laxatives. Chronic idiopathic constipation has a significant impact on the healthcare system, and it accounted for 3.92% of all ambulatory care visits in the U.S. in 2014.
High Cost to Hamper Chronic Idiopathic Constipation Treatment Market
Chronic idiopathic constipation continues to be associated with significant costs. It is like numerous other common conditions that contribute to greater morbidity and healthcare costs.
An article published in the American Journal of Managed Care stated that around 81% of cost of chronic idiopathic constipation treatment is associated with the use of medical services, including visits to prescribers and outpatient services. It is reported that pharmacy costs for chronic constipation patients with abdominal symptoms is 1.6 times higher than patients who did not have abdominal symptoms.
Cost of treatment is an important concern regarding the selection of treatment. Hence, higher cost associated with treatment hampers the market. For instance, the annual cost of treatment of chronic idiopathic constipation ranges from US$ 1,912 to US$ 7,522 per patient. In the U.S., direct medical cost of medical constipation is estimated at US$ 230 million per year.
Chronic Idiopathic Constipation Treatment Market: Competition Landscape
This report profiles major players operating in the global chronic idiopathic constipation treatment market based on various attributes and recent developments
The global chronic idiopathic constipation treatment market is highly fragmented with the presence of numerous global as well as regional players
Leading players operating in the global chronic idiopathic constipation treatment market include
- Bayer AG
- Allergan
- Bausch Health
- Sanofi
- Takeda Pharmaceutical Company
- SEBELA PHARMACEUTICALS
- Ironwood Pharmaceuticals, Inc.
- Albireo Pharma, Inc.
- Sucampo Pharmaceuticals, Inc. (Mallinckrodt)
- Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
Key Questions Answered in Chronic Idiopathic Constipation Treatment Market Report
- What is the scope of growth for product companies in the global chronic idiopathic constipation treatment market?
- What will be the Y-o-Y growth of the global chronic idiopathic constipation treatment market between 2020 and 2030?
- What is the influence of changing trends in technologies on the global chronic idiopathic constipation treatment market?
- Will North America continue to be the most profitable market for chronic idiopathic constipation treatment?
- Which factors are anticipated to hamper the global chronic idiopathic constipation treatment market during the forecast period?
- Which are the leading companies in the global chronic idiopathic constipation treatment market?
Chronic Idiopathic Constipation Treatment Market – Segmentation
Drug Class
- Serotonin-4 (5-Ht4) Receptor Agonist
- Prucalopride
- Others
- Guanylate Cyclase-C Agonist
- Plecanatide
- Linaclotide
- Laxatives
- Sodium Picosulphate
- Polycarbophil
- Others
- Stimulants
- Bisacodyl
- Senokot
- Others
- Others
Route of Administration
- Oral
- Rectal
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111832/2900
